Changes in the utilization of venlafaxine after the introduction of generics in Sweden [0.03%]
瑞典引入文拉法辛仿制药后的用药变化
Brian Godman,Marie Persson,Jamilette Miranda et al.
Brian Godman et al.
Background: There has been an appreciable increase in the prescribing efficiency of proton pump inhibitors, statins, and renin-angiotensin inhibitor drugs in Sweden in recent years. This has been achieved through multiple...
Pre-diagnosis excess acute care costs in Alzheimer's patients among a US Medicaid population [0.03%]
美国医疗补助人口中阿尔茨海默病患者诊断前急性护理费用过高
David S Geldmacher,Noam Y Kirson,Howard G Birnbaum et al.
David S Geldmacher et al.
Background and objectives: Prior research has documented that Alzheimer's disease (AD) is associated with increased costs from comorbid conditions. However, little is known about medical resource utilization and costs amo...
Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs [0.03%]
医疗保险按服务付费的急性髓系白血病主要患者：治疗模式、生存率和医疗保健资源利用及成本分析
Juliana Meyers,Yanni Yu,James A Kaye et al.
Juliana Meyers et al.
Background: Acute myeloid leukemia (AML) is the most common form of acute leukemia affecting adults, with incidence increasing with patient age. Previous studies have found that older AML patients, constituting the majori...
A pilot discrete choice experiment to explore preferences for EQ-5D-5L health states [0.03%]
一项针对EQ-5D-5L健康状态偏好的试验性离散选择实验研究
Richard Norman,Paula Cronin,Rosalie Viney
Richard Norman
Background: The EQ-5D-5L has recently been developed to improve the sensitivity of the widely used three-level version. Valuation studies are required before the use of this new instrument can be adopted. The use of discr...
Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis [0.03%]
帕金森病患者的药物治疗依从性及其直接医疗费用：回顾队列研究
Florent F Richy,Guilhem Pietri,Kimberly A Moran et al.
Florent F Richy et al.
Background: Parkinson's disease (PD) is a progressive neurological disorder for which, at present, there is no cure. Current therapy is largely based on the use of dopamine agonists and dopamine replacement therapy, desig...
Implications of a data-driven approach to treatment with growth hormone in children with growth hormone deficiency and Turner syndrome [0.03%]
基于数据的儿童生长激素缺乏症和特纳综合征治疗中使用生长激素的意义
Stefan Kaspers,Michael B Ranke,Donald Han et al.
Stefan Kaspers et al.
Background: Response to growth hormone (GH) therapy may vary between individual patients. Therefore the use of GH in children should be closely monitored to avoid over, under, or ineffective treatment regimens. The treatm...
The role of financial wellbeing, sociopolitical attitude, self-interest, and lifestyle in one's attitude toward social health insurance [0.03%]
财务福利、社会政治态度、自身利益和生活方式对社会健康保险态度的作用研究
Oliver Schnusenberg,Chung-Ping A Loh,Katrin Nihalani
Oliver Schnusenberg
Background: There has been continuous debate in the United States, Germany, and China about their respective healthcare systems. While these three countries are dealing with their own unique problems, the question of how ...
Su-Yeon Yu,Bong-Min Yang,Jin-Hyun Kim
Su-Yeon Yu
The South Korean Government recently announced a reform in the drug anti-rebate law, with the purpose of eradicating pervasive, unethical, and illegal rebate practices in pharmaceutical marketing. The main objective of this reform is to hav...
Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis [0.03%]
拨开层层迷雾：评估多发性硬化症治疗的成本效益
Annie Hawton,James Shearer,Elizabeth Goodwin et al.
Annie Hawton et al.
Background: Multiple sclerosis (MS) is a chronic neurological disorder, which can lead to a wide range of disabling symptoms. The condition has a significant negative impact on health-related quality of life, and the econ...
Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature [0.03%]
量化医疗干预措施的风险效益偏好的实证文献综述
A Brett Hauber,Angelyn O Fairchild,F Reed Johnson
A Brett Hauber
Decisions regarding the development, regulation, sale, and utilization of pharmaceutical and medical interventions require an evaluation of the balance between benefits and risks. Such evaluations are subject to two fundamental challenges-m...